AstraZeneca has now joined Pfizer in agreeing to sell its drugs to state Medicaid programs at “most-favored-nation” pricing ...

AstraZeneca secures a three-year tariff break after striking a landmark U.S. deal to cut drug prices and expand its domestic manufacturing.

As President Donald Trump's escalating tariff policies threaten to raise costs across global supply chains, one ...

AstraZeneca has become the second pharma group, after Pfizer, to reach an agreement with the Trump administration on a deal ...

President Trump on Tuesday announced that Pfizer had agreed to sell its products in the U.S. at “Most Favored Nation” pricing ...

This marks the second such deal that the Trump administration has negotiated. The first was with Pfizer. In both cases, the ...

Pfizer's strong pipeline of drugs and its fortress balance sheet make it an attractive investment at cheap valuation ...

The stock market often reacts negatively to President Donald Trump’s trade announcements. But it has finally responded favorably, to a 100% tariff on brand name and patented drugs.

According to DataM Intelligence, the Active Pharmaceutical Ingredients Market Size reached US$ 238.7 Billion in 2024, up from ...

President Donald Trump is scheduled to announce a deal on Friday about lowering U.S. drug prices, according to a White House ...